Abstract
Background: Silencing of two or more complementary signaling pathways can lead to cell death, while loss of any single genetic function does not show a severe phnotype, this kind of inter action is coined as “synthetic lethality”. Nowadays, synthetic lethality has become a widely used anti-cancer strategy.
Method: We reviewed the synthetic lethal interactions exploited in anticancer therapies before 2016. Conclusion: Synthetic lethality is a well proved anticancer strategy and more synthetic lethal interactions is being translated into clinical cancer therapies.Keywords: Synthetic lethality, targeted therapy, PARP inhibitors, drug resistance, cancer therapy, signaling pathways.
Graphical Abstract
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
NEOPLASIA and FERTILITY
Breast Cancer: Current Trends in Molecular Research
The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo
Nanotherapeutics for the Treatment of Hepatocellular Carcinoma
Topics in Anti-Cancer Research
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers
Herbal Medicine: Back to the Future
Thrombosis in Cancer: A Medical Professional's Guide to Cancer Associated Thrombosis
72
8
1